Last reviewed · How we verify

Ibuprofen suppository

Assaf-Harofeh Medical Center · FDA-approved active Small molecule

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Fever reduction, Mild to moderate pain, Inflammation.

At a glance

Generic nameIbuprofen suppository
Also known asno medicine
SponsorAssaf-Harofeh Medical Center
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaPain Management, Inflammation, Fever
PhaseFDA-approved

Mechanism of action

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses, pain signaling, and fever regulation. The suppository formulation delivers ibuprofen rectally for systemic absorption, providing an alternative route to oral administration, particularly useful in patients unable to take oral medications or requiring rapid onset of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: